15 Non-Hodgkin's Lymphoma 1 1 0 30 30 256 http://clinicaltrials.dfhcc.harvard.edu/trials/256 Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma This trial is comparing whether using a drug called sirolimus for graft versus host disease (GVHD) prevention can decrease the chance of the participant's lymphoma relapsing after transplantation, compared to using a standard GVHD prevention regimen without sirolimus. Since mTOR inhibitors have anti-lymphoma activity, their use after transplantation may lead to a decreased risk of relapse and hence better transplantation outcome. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma Phase 3 16 http://clinicaltrials.dfhcc.harvard.edu/trials/16 A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation Autologous peripheral blood stem cell transplantation combined with high dose chemotherapy is the treatment of choice given to patients with diffuse large-B cell lymphoma (DLBCL) following relapse of the disease. Although many people are cured of their lymphoma with this therapy, the disease comes back in a certain proportion of patients. The purpose of this study is to test the safety and effectiveness of the monoclonal antibody, CT-011, in patients with DLBCL who have received autologous peripheral blood stem cell transplantation. All final eligible patients will receive an IV infusion of CT-011 on Day 1 (30 to 90 days post autologous PBSCT). Treatment will be repeated every 42 days for a total of three courses with treatment visits on Days 1, 43, and 85. Follow-up for safety and clinical outcome will be conducted throughout the study till 18 months post autologous PBSCT. Approximately 70 patients will participate in this study. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma Phase 2 176 http://clinicaltrials.dfhcc.harvard.edu/trials/176 Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant That Uses Low Dose Chemotherapy in People With Leukemia or Lymphoma (BMT CTN #0604) A bone marrow transplant, which is a type of stem cell transplant, is a treatment option for people with leukemia or lymphoma. Recently, stem cell transplants using umbilical cord blood have become a treatment option for people with these types of cancers. This study will evaluate the effectiveness of a stem cell transplant using umbilical cord blood, along with lower doses of chemotherapy, to treat people with leukemia or lymphoma. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 11 Leukemia/MDS http://clinicaltrials.dfhcc.harvard.edu/diagnoses/11-leukemia-mds Phase 2 184 http://clinicaltrials.dfhcc.harvard.edu/trials/184 Efficacy and Safety Study of R935788 Tablets to Treat T-Cell Lymphoma Patients meeting specific inclusion and exclusion criteria will be enrolled in two stages, 19 patients in Stage 1 and 36 patients in Stage 2. Stage 2 will enroll if 4 or more patients exhibit a response at Week 8 or later in the study. All enrolled patients will be treated with R788 until disease progression. Efficacy will be assessed by tumor measurements using CT and PET (when indicated) scans and physical exam at baseline, and scans and physical exam of all disease-involved areas every 8 weeks until progression. Safety will be assessed by periodic physical exams, clinical laboratory studies, and adverse events. All patients will have a follow-up visit 30 days following last study drug treatment. Blood samples for PK assessment will be obtained from all patients enrolled in Stage 1 at protocol defined intervals. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma Phase 2 197 http://clinicaltrials.dfhcc.harvard.edu/trials/197 Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with an autologous stem cell transplant may allow more chemotherapy to be given so that more cancer cells are killed. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib after combination chemotherapy, monoclonal antibody therapy, and an autologous stem cell transplant may kill any remaining cancer cells or keep the cancer from coming back. PURPOSE: This randomized phase II trial is studying how well bortezomib works when given after combination chemotherapy, rituximab, and an autologous stem cell transplant in treating patients with mantle cell lymphoma. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma Phase 2 249 http://clinicaltrials.dfhcc.harvard.edu/trials/249 Effectiveness of a Blood Stem Cell Transplant That Uses Low Dose Chemotherapy in People With Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN #0701) Blood stem cell transplants are one treatment option for people with lymphoma or other types of blood cancers. For this type of treatment, family members or unrelated donors with a similar tissue type usually donate their blood stem cells to the transplant patients. This study will evaluate the effectiveness of a type of blood stem cell transplant that uses lower doses of chemotherapy in people with relapsed follicular non-Hodgkin's lymphoma (NHL). Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma Phase 2 294 http://clinicaltrials.dfhcc.harvard.edu/trials/294 Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma RATIONALE: Bortezomib and lenalidomide may stop the growth of mantle cell lymphoma by blocking blood flow to the cancer. Bortezomib may also stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with lenalidomide may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with lenalidomide works in treating patients with relapsed or refractory mantle cell lymphoma. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma Phase 2 481 http://clinicaltrials.dfhcc.harvard.edu/trials/481 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with newly diagnosed, HIV-associated Burkitt's lymphoma. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma Phase 2 516 http://clinicaltrials.dfhcc.harvard.edu/trials/516 Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma Everolimus is an oral mTOR inhibitor with demonstrated preliminary efficacy and safety in diffuse large B-cell lymphoma (DLBCL) in both preclinical and clinical studies. The purpose of this research study is to determine whether Everolimus plus rituximab is safe and effective in participants with relapsed or refractory DLBCL. Everolimus is an investigational drug that works by blocking a special protein that helps cancer cells grow. The safety and effectiveness of Everolimus in the treatment of DLBCL has not yet been fully determined and is still investigational. The other drug in this study, rituximab, is approved by the US Food and Drug Administration (FDA) for use in patients who have diffuse large B-cell lymphoma and certain other types of non-Hodgkin lymphoma. Rituximab is a drug that destroys both normal and cancerous B-cells. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma Phase 2 236 http://clinicaltrials.dfhcc.harvard.edu/trials/236 High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas The purpose of this clinical trial is to see if increased doses of rituximab are safe and effective for the initial treatment of indolent B-cell lymphomas. Rituximab (Rituxan) is a type of drug called an "antibody" that specifically targets B-cell lymphoma cells, and is approved by the FDA for the treatment of indolent B-cell non-hodgkin lymphomas and certain other types of non-hodgkin lymphomas. Standard doses currently used may not be achieving maximal efficacy. Higher doses have been shown to be safe in other clinical trials, and may offer superior efficacy to the current standard dose. This trial also employs intermittent maintenance doses of rituximab at the standard dose, which has been shown to prolong remissions and survival in patients with relapsed indolent B-cell lymphomas. This trial is designed to show that higher dose rituximab plus maintenance rituximab can achieve similarly good results to chemotherapy approaches, but without chemotherapy-related toxicity. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma Phase 2 327 http://clinicaltrials.dfhcc.harvard.edu/trials/327 Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies This is a Phase 1/2a, non-randomized, open-label, multi-center study designed to determine the Maximum Tolerated Dose (MTD) of Pralatrexate Injection and Gemcitabine with vitamin B12 and folic acid supplementation to patients with relapsed or refractory lymphoproliferative malignancies. Recruiting 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma Phase 1/Phase 2 337 http://clinicaltrials.dfhcc.harvard.edu/trials/337 Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies This study is to evaluate the highest tolerated dose, safety and activity of HCD122 in adults with non-Hodgkin's or Hodgkin's lymphoma who have received at least two prior therapies. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma Phase 1/Phase 2 362 http://clinicaltrials.dfhcc.harvard.edu/trials/362 A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 with the objective of defining the dose limiting toxicity and maximum tolerated dose. The Phase 2a portion of the study will evaluate ABT-263 at the defined recommended Phase 2 dose to obtain additional safety information and a preliminary assessment of efficacy. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma Phase 1/Phase 2 7 http://clinicaltrials.dfhcc.harvard.edu/trials/7 Reduced Intensity, Sequential Double Umbilical Cord Blood Transplantation Using Prostaglandin E2 (PGE2) The purpose of this research study is to determine the effects of 16, 16 Dimethyl-Prostaglandin E2 (dmPGE2) treatment on umbilical cord blood units to be used in transplantation. dmPGE2 treatment is being tested to see if it can improve the ability of umbilical cord blood stem cells to grow after transplantation. The growth of stem cells after transplantation is sometimes referred to as "engraftment". One of the major problems after umbilical cord transplantation is the time required for engraftment. After transplantation of two umbilical cord blood units, the average time to achieve engraftment is 21 days. In addition, up to 10% of patients who undergo umbilical cord blood transplantation never engraft, a potentially life-threatening condition. In laboratory studies, treatment of umbilical cord blood stem cells with dmPGE2 was shown to enhance engraftment. Recruiting 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma 17 Multiple Myeloma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/17-multiple-myeloma 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 11 Leukemia/MDS http://clinicaltrials.dfhcc.harvard.edu/diagnoses/11-leukemia-mds Phase 1 46 http://clinicaltrials.dfhcc.harvard.edu/trials/46 Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies The purpose of this study is to determine the dose that can be safely given to see what effect it may have on your cancer and to determine how the drug is distributed in the body. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 11 Leukemia/MDS http://clinicaltrials.dfhcc.harvard.edu/diagnoses/11-leukemia-mds Phase 1 129 http://clinicaltrials.dfhcc.harvard.edu/trials/129 Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-Cells in Patients With Relapsed Hematologic Malignancies The purpose of this research study is to evaluate the safety and efficacy of cell depletion in a donor lymphocyte infusion (DLI) product with the use of the CliniMACS machine. Previously, patients with hematologic malignancies who have relapsed after transplant have been given infusions of donor white blood cells calsed donor lymphocyte infusion (DLI) as a way to boost their immune function and fight cancer. Information from other research studies suggests that lowering the number of a certain type of white blood cell called CD25+ Tregs in the DLI may allow for a greater effect. In this research study, we are looking for the appropriate dose of DLI depleted of the CD25+ Treg white blood cells that can be given safely. Recruiting 17 Multiple Myeloma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/17-multiple-myeloma 11 Leukemia/MDS http://clinicaltrials.dfhcc.harvard.edu/diagnoses/11-leukemia-mds 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma Phase 1 163 http://clinicaltrials.dfhcc.harvard.edu/trials/163 Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma The purpose of this study is to compare the safety and immune activity of three doses of tumor vaccine. In recent years, researchers at the Dana-Farber Cancer Institute have discovered that vaccines made from patient's own cancer cell, that have been engineered in the laboratory to produce a protein called GM-CSF, can be effective in stimulating a powerful immune response specific to that cancer. GM-CSF is a naturally occuring hormone in the body that helps our immune system fight infections and diseases. One of the goals of this study is to determine whether these vaccinations will improve the immune system's ability to recognize and destroy the participant's lymphoma cells. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma Phase 1 413 http://clinicaltrials.dfhcc.harvard.edu/trials/413 Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed) The purpose of this research study is to determine the safety of the study drug pemetrexed, and the highest dose of this drug that can be given to people safely. Another goal of this research study is to gaim more information about how the body handles pemetrexed and how pemetrexed may work to treat the participant's cancer. Pemetrexed (also known as Alimta) has been approved by the FDA for the treatment of some lung cancers and has been shown to be effective in laboratory studies. Information from these studies suggests that pemetrexed may help to treat patients with either primary or secondary central nervous system lymphoma. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma Phase 1 921 http://clinicaltrials.dfhcc.harvard.edu/trials/921 Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant The proposed study is based on our observation of paradoxical tumor regression after rejection of the donor graft in conjunction with the results of our murine experiments. We hypothesize that clinically meaningful responses can be achieved in patients with advanced malignancies with a transplant strategy using nonmyeloablative conditioning and related mismatched donor stem cell transplant where the intention will be to initially achieve mixed chimerism which will be followed by recipient lymphocyte infusion (RLI) in an attempt to deliberately reject the donor graft. This will lead to the development of novel transplant strategies for achieving antitumor effects without the risk of graft versus host disease (GVHD). This proposed protocol is a Pilot Study that will evaluate the safety of this outpatient transplant strategy, i.e., establishment of initial mixed chimerism followed by RLI for donor graft rejection, in patients with advanced lymphomas, and multiple myeloma. In addition, because RLI have been reported to reverse ongoing GVHD, this approach might potentially reverse GVHD while achieving antitumor responses if this complication unexpectedly occurs. Recruiting 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 17 Multiple Myeloma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/17-multiple-myeloma Phase 1 1348 http://clinicaltrials.dfhcc.harvard.edu/trials/1348 A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies The study consists of two stages. In Stage 1, maximum tolerated dose (MTD) will be determined. In Stage 2, additional patients will be treated at the MTD of GDC-0152. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 38 Solid Tumor/Phase I http://clinicaltrials.dfhcc.harvard.edu/diagnoses/38-solid-tumor-phase-i Phase 1 104 http://clinicaltrials.dfhcc.harvard.edu/trials/104 Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials In order to learn more about follicular lymphoma and anti-cancer vaccines, we are collecting samples from people with this diagnosis. We then hope to make a vaccine from this tissue to help the immune system destroy cancer cells. We plan on keeping samples in the tissue bank indefinitely. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma N/A 241 http://clinicaltrials.dfhcc.harvard.edu/trials/241 Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma The purpose of this research study is to evaluate the overall response rate to imatinib mesylate in participants with relapsed or refractory T cell non-Hodgkin's lymphoma. This drug has been used in chronic myeloid leukemia and information from those other research studies suggests that it may help to treat T cell non-Hodgkin's lymphoma. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma N/A 311 http://clinicaltrials.dfhcc.harvard.edu/trials/311 Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma. Recruiting 17 Multiple Myeloma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/17-multiple-myeloma 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma 11 Leukemia/MDS http://clinicaltrials.dfhcc.harvard.edu/diagnoses/11-leukemia-mds N/A 1179 http://clinicaltrials.dfhcc.harvard.edu/trials/1179 PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin This clinical research study is to investigate the prevention of relapse in patients with diffuse large B cell lymphoma (DLBCL) using enzastaurin daily. This is a randomised trial which compares Enzastaurin to Placebo (dummy treatment), the chance of receiving Enzastaurin is 2 to 1. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 1263 http://clinicaltrials.dfhcc.harvard.edu/trials/1263 Phase II Study of Ofatumumab Plus ICE or DHAP Chemotherapy Regimen in Relapsed/ Refractory DLBCL The purpose of this study is to evaluate the safety and efficacy of ofatumumab used in combination with ICE or DHAP salvage chemotherapy regimens in subjects with relapsed or refractory DLBCL who are eligible for autologous stem cell transplant. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 1251 http://clinicaltrials.dfhcc.harvard.edu/trials/1251 A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma This is an open-label, multicenter, Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0980 administered to patients with incurable, locally advanced or metastatic solid malignancy or NHL that has progressed or failed to respond to at least one prior regimen or for which there is no standard therapy. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 38 Solid Tumor/Phase I http://clinicaltrials.dfhcc.harvard.edu/diagnoses/38-solid-tumor-phase-i 1254 http://clinicaltrials.dfhcc.harvard.edu/trials/1254 A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma This is an open-label, multicenter, Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0980 administered to patients with incurable, locally advanced or metastatic solid malignancy or NHL that has progressed or failed to respond to at least one prior regimen or for which there is no standard therapy. Recruiting 38 Solid Tumor/Phase I http://clinicaltrials.dfhcc.harvard.edu/diagnoses/38-solid-tumor-phase-i 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 1335 http://clinicaltrials.dfhcc.harvard.edu/trials/1335 Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma This is a Phase 1, single-arm, open-label, multi-center study designed to determine an effective and well-tolerated dose and schedule of pralatrexate when administered concurrently with vitamin B12 and folic acid supplementation to patients with relapsed or refractory CTCL. One cycle of treatment will be 3 or 4 weeks in duration, depending on treatment group. Treatment will continue until a patient meets criteria for discontinuation. Recruiting 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 1338 http://clinicaltrials.dfhcc.harvard.edu/trials/1338 A Trial In Patients With Advanced Cancer And Leukemia This is a phase 1, dose escalating study to determine the safety of PF-03084014 in patients with advanced cancer and leukemia Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 38 Solid Tumor/Phase I http://clinicaltrials.dfhcc.harvard.edu/diagnoses/38-solid-tumor-phase-i 11 Leukemia/MDS http://clinicaltrials.dfhcc.harvard.edu/diagnoses/11-leukemia-mds 1445 http://clinicaltrials.dfhcc.harvard.edu/trials/1445 Evaluating the Safety and Effectiveness of a Bone Marrow Transplant From Partially Matched Donors and Using Low Dose Chemotherapy in People With Leukemia or Lymphoma (BMT CTN #0603) Bone marrow transplants are one treatment option for people with leukemia or lymphoma. Family members or unrelated donors with a similar type of bone marrow usually donate their bone marrow to the transplant patients. This study will evaluate the effectiveness of a new type of bone marrow transplant—one that uses lower doses of chemotherapy and bone marrow donated from family members with only partially matched bone marrow—in people with leukemia or lymphoma. Recruiting 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma 11 Leukemia/MDS http://clinicaltrials.dfhcc.harvard.edu/diagnoses/11-leukemia-mds 17 Multiple Myeloma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/17-multiple-myeloma 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma